Levocetirizine/pseudoephedrine

Drug Profile

Levocetirizine/pseudoephedrine

Alternative Names: Cossac L; HCP 0703; Pseudoephedrine/levocetirizine

Latest Information Update: 13 May 2015

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antiallergics; Decongestants; Nonsedating antihistamines; Piperazines; Propanolamines; Small molecules
  • Mechanism of Action Alpha adrenergic receptor agonists; Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic rhinitis

Most Recent Events

  • 30 Apr 2013 Hanmi Pharmaceutical completes a phase III trial in Allergic rhinitis in South Korea (NCT01509209)
  • 01 May 2011 Phase-III clinical trials in Allergic rhinitis in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top